Skip to Content

Ashish M. Kamat, MD, MBBS, FACS

Present Title & Affiliation

Primary Appointment

Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, and a graduate of the AUA Leadership Program.

Dr Kamat’s expertise is in multidisciplinary management of urologic cancers with an emphasis bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). While he is a busy surgeon, he maintains an active research portfolio to improve the care of patients. Dr Kamat’s efforts are directed towards identifying predictors of response to therapy - especially immunotherapy - as a first step towards personalized cancer therapeutics. A major focus of his laboratory research is to develop novel treatments for bladder cancer and identify resistance mechanisms and ways to overcome them.  He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE.

Dr Kamat has authored over 200 publications, editorials & book chapters in prestigious journals; he is listed in 'Who's Who in Medicine' and ‘Best Doctors in America’ and has won the Compassionate Doctor Award from patient groups. He is an exceptional educator nominated twice for the Robert M. Chamberlain Distinguished Mentor Award and has been invited as a visiting professor to several universities across the world.

Dr Kamat is Co President,International Bladder Cancer Network, Chair, Bladder Cancer Think Tank (2015), Chair, Bladder Cancer Task Force for SITC, actively participates in various global urologic efforts, and serves on the board of regional and national societies for Urology.

Further Reading:

Research Interests

Immunotherapy, Personalized Therapeutics, Organ Conservation, Novel therapies, Stem Cell Biology

Education & Training

Degree-Granting Education

1994 Seth G. S. Medical College & King Edward Memorial Hospital, University of Bombay, Bombay, India, MBBS (MD), Medicine, Surgery
1988 University of Bombay - Jai Hind College, Bombay, India, HSC, Biologic Sciences

Postgraduate Training

7/2001-7/2003 Fellowship, Urologic Oncology, MD Anderson Cancer Center, Houston, TX

Board Certifications

2/2005 American Board of Urology


Academic Appointments

Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-8/2014
Assistant Professor, Urology and Cancer Biology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2003-8/2008

Administrative Appointments/Responsibilities

Residency Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005-2014

Other Appointments/Responsibilities

Chair, Bladder Cancer Task Force, Society of Immunotherapy for Cancer (SITC), Milwaukee, WI, 2014-present
State Representative (Texas), South Central Section of AUA, Houston, 2011-present
Co-President, International Bladder Cancer Network (IBCN), Furth, Germany, 2010-present
Member, Young Urologist Committee, American Urological Association, Linthicum, MD, 2009-2013
Member, Practice Guidelines Committee, American Urological Association, Linthicum, MD, 2009-2011
Member, Board of Directors, South Central Section AUA, Schaumburg, IL, 2008-present
Medical Director, Bladder Cancer Support Group, UT - MDACC, Houston, TX, 2007-2014
Associate Member, Center for Biomedical Engineering, Houston, TX, 2003-2007


Consultant, National Cancer Institute (NCI) Bladder Task Force, Bethesda, MD, 4/2010-present
Scientific Advisory Board, National Bladder Cancer Think Tank, Bethesda, MD, 2007-present

Institutional Committee Activities

Member, Promotion and Tenure Committee, 2015-present
Member, GMEC Budget Committee, 2013-present
Member/Advisor, Surgical Services Advisory Committee, 2011-present
Member, MD Anderson India Steering Committee, 2008-present
Co-Director, GU SPORE Career Development Program, 2008-2009
Member, POE Operating Room Safety Council, 2007-present
Member, Clinical Effectiveness Committee, 2007-2008
Urology Representative, Faculty Senate, 2006-2008
Member, Division of Surgery Education/Training Committee, 2004-2005
Member, OR Committee, 2003-present
Member, Graduate Medical Education Committee, 2002-present

Honors and Awards

2016 Faculty Educator Award, MD Anderson Cancer Center
2016 Outstanding Program Director Award (Nominee), MD Anderson Cancer Center GME
2014-present Chair, Bladder Cancer Task Force, Society of Immunotherapy for Bladder Cancer, ITC (Society of Immunotherapy for Bladder Cancer)
2014 Robert M. Chamberlain Distinguished Mentor Award Nominee, MD Anderson Cancer Center
2013 Top Reviewer in Urology, AUA
2012 Mentor Award Nominee, MD Anderson Cancer Center
2012 Outstanding Reviewer in 2012 Award, The Journal of Urology
2011-present Compassionate Doctor Award, Patient Recognition
2008-present AUA Leadership Program Award, American Urological Association
2008-present Best Doctors in America
2008-present Board of Directors, South Central Section of the American Urological Assciation
2007-present Fellow, American College of Surgeons (FACS), American College of Surgeons
2007 Excellent Reviewer Award, UT MD Anderson Cancer Center
2005-present Who's Who in America
2004 Faculty Award, AACR
2003 Bladder SPORE Developmental Research Program Award, NCI
2002 Scholar in Training Award, American Association for Cancer Research
2001 Outstanding Laparoendoscopist, Society of Laparoendoscopic Surgeons
2000 Best Published Papers in "Urology", AUA
2000 First Prize, American College of Surgeons
1999 First Prize, American College of Surgeons
1999 First Prize, West Virginia University
1999 Scholars in Urology (National), Pfizer
1999 Second prize, University of Pittsburgh
1997 Oustanding/Best Paper Presentation, West Virginia University
1992 Dr. L. H. Hiranandani Scholarship in Otorhinolaryngology, University of Bombay
1991 Distinctions in Forensic Medicine and Medical Jurisprudence, Pharmacology,Microbiology, Biochemistry and Preventive and Social Medicine, University of Bombay
1991 Gold Medal Performance, University of Bombay
1991 Manorama Vijayrat Hazarat Prize for Highest Cumulative Score, University of Bombay
1991 Seth Khimchand Amulakh Prize for Excellence in Pharmacology, University of Bombay
1991 Shamdasani Foundation Scholarship for Standing First in University, University of Bombay

Professional Memberships

American Association of Cancer Research
Member, 2003-present
American College of Surgeons (FACS)
Member, 2005-present
American Medical Association
Member, 1999-present
American Society of Clinical Oncology
Member, 2004-present
American Urological Association
Member, 1999-present
AUA Health Policy Committee, Linthicum, MD
Member, 7/2009-present
AUA Young Urologist Committee
South Central Section Representative, 11/2008
Dutch Cancer Society, Research & Development
Member, 2007
Harris County Medical Society, TX
Member, 2001-present
International Bladder Cancer Network, Houston, TX
Vice President, 2010-present
Leadership Program of American Urologic Association
Member, 7/2008-2009
Society Internationale d'Urology
Member, 2005-present
Society of Urologic Oncology
Editorial Board Appointment, 8/2011-present
South Central Section of the American Urological Association
Board of Directors, 2003-present
Southwest Oncology Group (SWOG)
Member, 2003-present
Texas Medical Association, TX
Member, 2001-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Jinesh GG, Kamat AM. Blebbishield emergency program: an apoptotic route to cellular transformation. Cell Death Differ 23(5):757-8, 5/2016. e-Pub 3/11/2016. PMCID: PMC4832111.
2. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. e-Pub 4/21/2016. PMID: 27101100.
3. Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S, Kamat AM. CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol. e-Pub 3/30/2016. PMID: 27038699.
4. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein J, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. e-Pub 3/14/2016. PMID: 26988609.
5. Parker WP, Ho PL, Boorjian SA, Melquist JJ, Thapa P, Holzbeierlein JM, Frank I, Kamat AM, Lee EK. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World J Urol. e-Pub 3/4/2016. PMID: 26943643.
6. Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Eur Urol. e-Pub 2/24/2016. PMID: 26922408.
7. Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol 69(2):197-200, 2/2016. e-Pub 6/25/2015. PMCID: PMC4691211.
8. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol 34(2):59.e1-8, 2/2016. e-Pub 10/1/2015. PMID: 26421586.
9. Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. e-Pub 1/25/2016. PMID: 26811532.
10. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Barnes HF, Matullo G, Golka K, Gago-Dominguez M, Taylor J, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Scaredote C, Selinski S, Hengstler JG, Gerullis H, Ovsianikov D, Blaszkewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-de-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. e-Pub 1/4/2016. PMID: 26732427.
11. Jinesh GG, Laing NM, Kamat AM. Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. Biochem J 473(1):99-107, 1/1/2016. e-Pub 10/27/2015. PMID: 26508734.
12. Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-ζ to p47(phox) interaction is necessary for transformation from blebbishields. Sci Rep 6:23965, 2016. e-Pub 4/4/2016. PMCID: PMC4819220.
13. Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, Wu X. Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol 194(6):1771-6, 12/2015. e-Pub 7/11/2015. PMID: 26173102.
14. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46(12):1808-14, 12/2015. e-Pub 8/12/2015. PMID: 26364859.
15. Takeuchi H, Mmeje CO, Jinesh GG, Taoka R, Kamat AM. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep 34(5):2738-44, 11/2015. e-Pub 8/21/2015. PMCID: PMC4583834.
16. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. e-Pub 9/2/2015. PMID: 26343003.
17. Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Grossman HB, Dinney CP. A novel FISH-based definition of BCG failure to enhance recruitment into clinical trials of intravesical therapies. BJU Int. e-Pub 6/1/2015. PMID: 26032953.
18. Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, Dinney CP, Wu X. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). e-Pub 4/20/2015. PMID: 25896234.
19. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. e-Pub 3/24/2015. PMID: 25800393.
20. Taoka R, Williams SB, Ho PL, Kamat AM. In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. Can Urol Assoc J 9(3-4):E109-13, Mar-Apr, 3/2015. PMCID: PMC4374995.
21. Ho PL, Williams SB, Kamat AM. Immune therapies in non-muscle invasive bladder cancer. Curr Treat Options Oncol 16(2):315, 2/2015. PMID: 25757877.
22. Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, Kavalieris L, Darling DG. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 15:45, 2015. e-Pub 5/12/2015. PMID: 25962444.
23. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol 142(6):864-71, 12/2014. PMID: 25389341.
24. Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK. The Effect of Concomitant Carcinoma In Situ on Neoadjuvant Chemotherapy for Urothelial Cell Carcinoma of the Bladder: Inferior Pathological Outcomes but No Effect on Survival. J Urol. e-Pub 11/11/2014. PMID: 25451834.
25. Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol. e-Pub 10/8/2014. PMID: 25306288.
26. Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat A. Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression who Have Failed Treatment with Bacillus Calmette-Guérin. J Urol. e-Pub 10/3/2014. PMID: 25286009.
27. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 11(10):589-96, 10/2014. e-Pub 9/23/2014. PMID: 25245244.
28. Kamat AM, Lamm DL. Predicting response to bacillus calmette-guérin: time to look beyond the ages. Eur Urol 66(4):702-3, 10/2014. e-Pub 6/23/2014. PMID: 24968969.
29. Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical Outcomes in cT1 Micropapillary Bladder Cancer. J Urol. e-Pub 9/21/2014. PMID: 25254936.
30. Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol. e-Pub 8/19/2014. PMID: 25159014.
31. Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. Urology. e-Pub 8/28/2014. PMID: 25174656.
32. Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J. Defining and Treating the Spectrum of Intermediate-Risk NMIBC. J Urol 192(2):305-15, 8/2014. e-Pub 3/2014. PMID: 24681333.
33. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda . Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. e-Pub 7/15/2014. PMID: 25027329.
34. Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urol Oncol. e-Pub 6/12/2014. PMID: 24931270.
35. Pisters AL, Kamat AM, Wei W, Leibovici D, Liu J, Grossman HB, Butler CE. Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. Urology 83(6):1427-32, 6/2014. e-Pub 4/24/2014. PMID: 24768021.
36. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88(5):1048-56, 4/1/2014. PMID: 24661658.
37. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 83(4):863-8, 4/2014. e-Pub 1/31/2014. PMID: 24485993.
38. Onaiwu CO, Ramirez PT, Kamat A, Pagliaro LC, Euscher EE, Schmeler KM. Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva. Gynecol Oncol Case Rep 8:27-9, 4/2014. e-Pub 4/12/2014. PMCID: PMC4009448.
39. Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. e-Pub 3/15/2014. PMID: 24745616.
40. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. e-Pub 3/13/2014. PMID: 24633966.
41. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. Eur Urol. e-Pub 2/26/2014. PMID: 24630419.
42. Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol. e-Pub 1/9/2014. PMID: 24411790.
43. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1), 1/2014. PMID: 23911605.
44. Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, Böhle A, Kamat AM, Colombel M, Soloway M. Defining Progression in Non-Muscle Invasive Bladder Cancer (NMIBC): It's Time for a New, Standard Definition. J Urol 191(1), 2014. PMID: 23973937.
45. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martinw C, Moreno J, Kamat AM. Alvimopan, a Peripherally Acting Mu-Opioid Receptor Antagonist, Is Associated With Reduced Costs After Radical Cystectomy-Economic Analysis of a Phase 4 Randomized, Controlled Trial. J Urol. e-Pub 12/2013. PMID: 24342144.
46. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G, Grubb R, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. e-Pub 11/23/2013. PMID: 24163127.
47. Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol 39(6):817-22, Nov-Dec, 11/2013. PMID: 24456786.
48. Jinesh G G, Lee EK, Tran J, Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol 31(8), 11/2013. PMID: 22717623.
49. Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 112(6):742-50, 10/2013. e-Pub 3/2013. PMCID: PMCPMC3933735.
50. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists(☆). Urol Oncol 31(7):1171-7, 10/2013. e-Pub 4/24/2012. PMID: 22534087.
51. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I Trial of Intravesical Recombinant Adenovirus-Mediated Interferon-α2b Formulated in Syn3 for BCG failures in Non-Muscle-Invasive Bladder Cancer. J Urol 190(3):850-6, 9/2013. e-Pub 3/15/2013. PMID: 23507396.
52. Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical Significance of Ureteral "Skip Lesions" at the Time of Radical Cystectomy: the Md-Anderson Experience and Review of Literature. BJU Int. e-Pub 7/2/2013. PMID: 24053608.
53. Lee EK, Gerald GJ, Laing NM, Choi W, McConkey D, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther 14(9). e-Pub 6/19/2013. PMID: 23792592.
54. Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer 108(11):2372-80, 6/11/2013. e-Pub 4/30/2013. PMCID: PMC3681021.
55. Lee EK, Ye Y, Kamat AM, Wu X. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119(9):1643-51, 5/1/2013. e-Pub 3/25/2013. PMID: 23529717.
56. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results. Cancer 119(3):540-7, 2013. PMID: 22914978.
57. Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM.. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 20(3):382-95, 2013. PMID: 23175184.
58. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol 31(6):812-26, 2013. PMID: 22056403.
59. Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol 31(4):480-6, 2013. PMID: 21478035.
60. Fernández MI, Gong Y, Ye Y, Lin J, Chang DW, Kamat AM, Wu X. Gamma-H2AX Level in Peripheral Blood Lymphocytes as a Risk Predictor for Bladder Cancer. Carcinogenesis 34(11), 2013. PMID: 23946494.
61. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI.. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. Eur Urol. 63(1):4-15, 2013. PMID: 23083902.
62. Davis JW, Kamat AM.. Lymphadenectomy with robotic cystectomy. Curr Urol Rep 14(1):Feb;14(1):59-63, 2013. PMID: 23138180.
63. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A.. Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. PMID: 22564397.
64. Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD.. ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy. Mol Cell 50(1):16-28, 2013. PMID: 23434374.
65. Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X.. Genetic variations in the transformation growth factor Beta pathway as predictors of bladder cancer risk. PLoS One 2(12), 12/2012. PMID: 23251617.
66. Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 13(13). e-Pub 11/2012. PMID: 22895070.
67. Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X.. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with bacillus calmette-guérin. PLoS One 7(6), 6/2012. PMID: 22701660.
68. Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PG, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World J. Urol 30(6):807-14, 6/2012. PMID: 22832587.
69. Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvent therapies after radical cystectomy. BJU Int. 110(11):590-5, 6/2012. PMID: 22758775.
70. Jinesh G G, Chunduru S, Kamat AM.. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol. 92(1):233-44, 6/2012. PMID: 22517918.
71. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of flourescence in situ hybridization to predict response to bacillus calmette-guerin therapy for bladder cancer: results of a prespective trial. J Urol 187(3). e-Pub 1/2012. PMID: 22245325.
72. Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 30(6):772-8, 2012. PMID: 23218068.
73. Jinesh G G, Kamat AM.. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology 1(7):1161-1162, 2012. PMID: 23170264.
74. Fernandez MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role FISH and cytology in upper urinary tract surveillance after radical cystectomoy for bladder cancer. Urol. Oncol. 30(6):821-4, 2012. PMID: 21396845.
75. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 30(3):266-72, 2012. PMID: 20869888.
76. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20(21):4282-9, 11/1/2011. e-Pub 8/8/2011. PMCID: PMC3188994.
77. Gu J, Chen M, Shete S, Amos Cl, Kamat A, Ye Y, Lin J, Dinney CP, Wu X.. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 4(4):514-21, 4/2011. PMID: 21460395.
78. Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP.. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 107(6):898-904, 3/2011. PMID: 21244604.
79. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF.. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 2011. PMID: 21354598.
80. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU International 108(7):1119-23, 2011. PMID: 21426474.
81. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. J Urol 185(1):79-83, 2011. PMID: 21074799.
82. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-61, 2011. PMCID: PMC2950900.
83. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 10(9):885-92, 11/2010. e-Pub 11/2010. PMID: 20814238.
84. Xu AD, Ng CS, Kamat A, Grossman HB, Dinney C, Sandler CM. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol 195(4):959-65, 10/2010. PMID: 20858825.
85. Matin SF, Kamat AM, Grossman HB. High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound Med 29(9):1277-84, 9/2010. PMID: 20733182.
86. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 7/1/2010. PMID: 20564621.
87. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int 106(1):56-61, 7/2010. e-Pub 12/2009. PMID: 20002676.
88. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 5/2010. e-Pub 5/2010. PMID: 20460488.
89. Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer 2(116):340-346, 1/15/2010. PMID: 19908257.
90. Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat A, Safe S. Activation of Nerve Growth Factor-Induced B{alpha} by Methylene-Substituted Diindolylmethanes in Bladder Cancer Cells Induces Apoptosis and Inhibits Tumor Growth. Mol Pharmacol 77(3):396-404, 2010. PMID: 20023005.
91. Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Dinney CP. Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology 76(6):1419-24, 2010. PMID: 20472264.
92. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer. Eur Urol 57(1):60-70, 2010. PMID: 19740595.
93. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. Eur Urol 57(2):300-9, 2010. PMID: 19766384.
94. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin Potentiates the Antitumor Effects of Gemcitabine in an Orthotopic Model of Human Bladder Cancer through Suppression of Proliferative and Angiogenic Biomarkers. Biochem Pharmacol 79(2):218-28, 2010. PMID: 19682434.
95. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL, Zhang HZ, Kamat A, Katz RL. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 118(5):259-68, 2010. PMID: 20665656.
96. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 3(10):1235-45, 2010. PMID: 20858759.
97. Davis JW, Kamat A, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized? BJU Int 105(8):1148-54, 2010. PMID: 19874300.
98. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10):1402-12, 2010. PMID: 20132195.
99. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site Hernias Occurring After the Use of Bladeless Radially Expanding Trocars. Urology 75(3):574-80, 2010. PMID: 19854489.
100. Momoh AO, Kamat AM, Butler CE. Reconstruction of the pelvic floor with human acellular dermal matrix and omental flap following anterior pelvic exenteration. J Plast Reconstr Aesthet Surg 63(12):2185-7, 2010. PMID: 20399719.
101. Svatek RS, Fisher MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Kennedy KA, Dinney CP. Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. J Urol 183(3):929-34, 2010. PMID: 20083264.
102. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69(23):8958-66, 12/2009. e-Pub 11/2009. PMID: 19903839.
103. Fisher MB, Svatek RS, Hegarty PK, McGinniss JE, Hightower C, Grossman HB, Kamat AM, Dinney CP, Matin SF. Cardiac history and risk of post-cystectomy cardiac complications. Urology 74(5):1085-9, 11/2009. e-Pub 9/16/2009. PMCID: PMC2784244.
104. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 40(10):1448-52, 10/2009. e-Pub 5/19/2009. PMID: 19454359.
105. Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115(18):4096-103, 9/15/2009. PMID: 19536899.
106. Lin J, Kamat A, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev 18(7):2090-7, 7/2009. e-Pub 6/23/2009. PMID: 19549811.
107. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. J Clin Oncol 27(16):2592-7, 6/1/2009. e-Pub 5/4/2009. PMID: 19414678.
108. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8). e-Pub 2/2009. PMCID: PMC2650334.
109. Manas Jain, Surena F. Matin, Ashish M. Kamat. Inferior Vena Cava Atresia Associated with von Hippel-Lindau Masquerading as Metastatic Testicular Cancer. Curr Urol 2(4):214-216, 2/2009. e-Pub 2009.
110. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 1/2009. e-Pub 1/2009. PMID: 19156903.
111. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 1/2009. e-Pub 10/2008. PMCID: PMCPMC2674246.
112. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Wood CG. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224-33, 1/2009. e-Pub 1/2009. PMID: 19156917.
113. Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 7(12):3825-33, 12/2008. PMID: 19074857.
114. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 9/30/2008. e-Pub 9/25/2008. PMCID: PMC2567480.
115. Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol 180(1):164-7; discussion 167, 5/2008. e-Pub 5/2008. PMID: 18485384.
116. Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 40(4):893-9, 3/2008. e-Pub 3/2008. PMID: 18317944.
117. Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26(1):121-6, 1/2008. PMID: 18165646.
118. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 26(6):595-9, Nov-Dec, 1/2008. e-Pub 1/2008. PMID: 18367105.
119. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer. Clin Cancer Res 14(1):224-229, 1/2008. PMID: 18172274.
120. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178(6):2302-2306, 12/2007. e-Pub 10/15/2007. PMID: 17936803.
121. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110(12):2700-2708, 12/2007. PMID: 17948916.
122. Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer 111(5):323-329, Jan-Feb, 10/2007. e-Pub 8/2007. PMID: 17721991.
123. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10):2160-2165, Jan-Feb, 10/2007. e-Pub 8/2007. PMID: 17728339.
124. Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18(8):839-45, Jan-Feb, 10/2007. PMID: 17593531.
125. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110(4):764-9, Jan-Feb, 8/15/2007. PMID: 17614317.
126. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70(2):252-6, 8/2007. PMCID: PMC2034451.
127. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, Jan-Feb, 7/1/2007. PMID: 17542024.
128. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177(4):1330-4; discussion 1334, Jan-Feb, 4/2007. PMID: 17382725.
129. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6(3):1022-30, Jan-Feb, 3/2007. PMID: 17363495.
130. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 356(12):1276; author reply 1276-7, Jan-Feb, 3/2007. PMID: 17377172.
131. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. Eur Urol 52(3):769-776, Jan-Feb, 1/2007. PMCID: PMC2691552.
132. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-8, 1/2007. PMID: 17162023.
133. Spiess PE, Brown GA, Tannir NM, Tu Shi-Ming, Liu P, Kamat AM. Predicting diseas progression in patients with viable tumor at post-chemotherapy rplnd. JUrol 177(4):278, 2007.
134. Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM. Recurrence in patients with PNO at RPLND: can we predict which patients are at risk? J Urol 177(4):330, 2007.
135. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25(1):38-45, Jan-Feb, 2007. PMID: 17208137.
136. Black PC, Kassouf W, Brown GA, Liu P, Kamat AM, Nogueras GM, Munsell MF, Siefker-Radtke A, Millikan RE, Grossman HB, Dinney CP. Variant histology in bladder cancer-experience in 1246 patients undergoing cystectomy. J Urol 177(4):502, 2007.
137. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176(4 Pt 1):1642-7, 10/2006. PMID: 16952707.
138. Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107(1):54-9, 7/2006. PMID: 16708356.
139. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 67(4):769-73, 2006. PMID: 16584762.
140. Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 2006. PMID: 16952661.
141. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12):3032-41, 2006. PMID: 17172406.
142. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176(1):53-7; discussion 57, 2006. PMID: 16753366.
143. Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 67(3):466-71, 2006. PMID: 16527559.
144. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3):631-9, 2006. PMID: 16802288.
145. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66(1):412-8, 2006. PMID: 16397256.
146. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int 98(6):1176-80, 2006. PMID: 17125474.
147. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175(6):2058-62, 2006. PMID: 16697803.
148. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-90, 2006. PMID: 16944541.
149. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 107(7):1491-5, 2006. PMID: 16894527.
150. Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175(3 Pt 1):864-9, 2006. PMID: 16469567.
151. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881-5, 2006. PMID: 16469571.
152. Dhanani NN, Kamat AM. Treatment of bladder cancer in cardiac transplant patients. Int Urol Nephrol 38(3-4):477-9, 2006. PMID: 17115247.
153. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67(3):518-23, 2006. PMID: 16527570.
154. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107(7):1503-10, 2006. PMID: 16944534.
155. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 10/2005. PMCID: PMC1550288.
156. Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol 61(1):14-19, 2005. PMID: 15629589.
157. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66(6):1209-12, 2005. PMID: 16360444.
158. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 2005. PMID: 16280761.
159. Shapiro A, Vakar F, Kamat AM. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guerin instillation masquerading as peritoneal carcinomatosis. Urol Oncol 23(5):352-3, Sep-Oct, 2005. PMID: 16144670.
160. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with. Int J Radiat Oncol Biol Phys. 61(4):993-1002, 2005. PMID: 15752878.
161. Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 66(2):327-31, Mar-Apr, 2005. PMID: 16040084.
162. Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 23(2):130-1, Mar-Apr, 2005. PMID: 15869998.
163. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1):134-40, Mar-Apr, 2005. PMID: 16111581.
164. Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1):101-4, May-Jun, 2005. PMID: 15389800.
165. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174(4 Pt 1):1262-5, 2005. PMID: 16145389.
166. Kamat AM, Lamm DL. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3):457-60, May-Jun, 2004. PMID: 15028437.
167. Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, May-Jun, 2004. PMID: 15076299.
168. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63(1):46-50, May-Jun, 2004. PMID: 14751346.
169. Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7):939-44, May-Jun, 2004. PMID: 15253325.
170. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63(6):1132-7, May-Jun, 2004. PMID: 15183966.
171. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3):279-90, May-Jun, 2004. PMID: 15026548.
172. Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, May-Jun, 2003. PMID: 14532792.
173. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170(5):1860-3, May-Jun, 2003. PMID: 14532793.
174. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ,. Nuclear factor-kappaB mediates angiogenesis and metastasis of human. Clin Cancer Res 9(7):2786-2797, 2003.
175. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, May-Jun, 2003. PMID: 14532795.
176. Kamat AM, York T, DeBord J. Anastomotic fistula after ileal loop urinary diversion presenting as persistent urethral drainage. J Urol 165(3):906-907, 2001. PMID: 11176505.
177. Kamat AM, DeHaven JI, Lamm DL. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1):56-61, 1999. PMID: 10414727.

Invited Articles

1. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am 29(2):237-52, viii, 4/2015. e-Pub 1/9/2015. PMID: 25836932.
2. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol 33(2):53-64, 2/2015. e-Pub 7/25/2014. PMID: 25065704.
3. Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol 32(7):1049-50, 10/2014. e-Pub 10/29/2014. PMID: 25443142.
4. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. e-Pub 6/11/2014. PMID: 24921905.
5. Jinesh GG, Willis DL, Kamat AM. Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Curr Stem Cell Res Ther. e-Pub 11/13/2013. PMID: 24236543.
6. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urol Oncol 31(7):968-73, 10/2013. e-Pub 1/31/2012. PMID: 22300756.
7. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 23(5):435-43, 9/2013. e-Pub 7/2013. PMID: 23880739.
8. Shah JB, Kamat AM. Strategies for optimizing bacillus calmette-guerin. Urol Clin North Am 40(2):211-8, 5/2013. PMID: 23540779.
9. Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 25(10):951-8, 960, 9/2011. PMID: 22010395.
10. Kamat AM. Is repeat transurethral resection needed for minimally invasive t1 urothelial cancer? J Urol 186(3):788-9, 9/2011. e-Pub 7/2011. PMID: 21794877.
11. Dickstein RJ, Kamat AM. Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) 25(14):1396-405, 2011. PMID: 22329191.
12. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther 5(4):387-95, 12/2010. PMID: 20955163.
13. Kassouf W, Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG. Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J 4(3):168-73, 6/2010. PMCID: PMC2874590.
14. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol 28(3):334-7, May-Jun, 5/2010. PMID: 20439033.
15. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol 28(3):338-42, May-Jun, 5/2010. PMID: 20439034.
16. Kamat AM, Lotan YR. Perioperative intravesical therapy after transurethral resection for bladder cancer. J Urol 183(1):19-20, 1/2010. PMID: 19913827.
17. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep 2, 2010. e-Pub 6/2010. PMCID: PMC2950042.
18. Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol 27(6):585-91, Nov-Dec, 11/2009. e-Pub 1/2009. PMID: 19162510.
19. Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9(6):815-20, 6/2009. PMID: 19496718.
20. Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 9(6):807-13, 6/2009. PMID: 19496717.
21. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 2009. PMID: 20012924.
22. Hegarty PK, Kamat AM. Management of bladder cancer. Minerva Urol Nefrol 60(4):255-64, 12/2008. PMID: 18923362.
23. La Rochelle J, Kamat A, Grossman HB, Pantuck A. Chemoprevention of bladder cancer. BJU Int 102(9 Pt B):1274-8, 11/2008. PMID: 19035892.
24. Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 26(1):39-44, 2/2008. e-Pub 12/2007. PMID: 18092171.
25. Agarwal PK, Kamat AM. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian J Urol 24(1):77-83, 1/2008. PMCID: PMC2684254.
26. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3(9):472-3, 9/2006. PMID: 16964186.
27. Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 6(8):1283-94, 8/2006. PMID: 16925494.
28. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 176(5):1914-20, 2006. PMID: 17070211.
29. Brassell SA, Kamat AM. Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the bladder. J Natl Compr Canc Netw 4(10):1027-1036, 2006. PMID: 17112451.
30. Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6):1283-1294, May-Jun, 2004. PMID: 15606331.
31. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, May-Jun, 2004. PMID: 15324694.
32. Herring JC, Kamat AM. Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6):1047-1056, May-Jun, 2004. PMID: 15606332.
33. Kamat AM. Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6):799-808, May-Jun, 2003. PMID: 14686702.
34. Kamat AM, Dinney CPN. Molecular aspects of metastases in bladder cancer. Urol Integ 8(2):180-189, 2003.
35. Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am 29(1):1-12, May-Jun, 2002. PMID: 12109342.
36. Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep 2(1):62-69, May-Jun, 2001. PMID: 12084297.
37. Kamat AM, Lamm DL. Current trends in intravesical therapy for bladder cancer. Contemporary Urology 12(8):64-88, 2000.
38. Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J 96(3):449-454, May-Jun, 2000. PMID: 14619137.
39. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 55(2):161-168, Nov-Dec, 2000. PMID: 10688071.
40. Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 161(6):1748-60, 1999. PMID: 10332429.
41. Kamat AM, Lamm DL. Intravesical therapy for superficial bladder cancer. Inf Urol 12(2):37-45, 1999.
42. Kamat AM, Lamm DL. Role of BCG in treatment of superficial bladder cancer. Indian Journal of Urology 16(1):1-9, 1999.


1. Morales EE, Aggarwal BB, Kamat AM. Natural Compounds Targeting STAT3 Mediated Inflammation. Eur Urol 69(3):405-6, 3/2016. e-Pub 10/9/2015. PMID: 26454706.
2. Williams SB, Kamat AM. Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure? BJU Int. e-Pub 2/24/2016. PMID: 26917454.
3. Williams SB, Kamat AM, Lamm DL. Pelvic Recurrence Following Radical Cystectomy: A Call to Arms. BJU Int. e-Pub 10/13/2014. PMID: 25307493.
4. Thomas AZ, Kamat AM. Venous thromboembolism and bleeding risk in bladder cancer. Oncology (Williston Park) 28(10):854-5, 861, 10/2014. PMID: 25323611.
5. Kamat AM, Porten S. Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. Eur Urol. e-Pub 10/26/2013. PMID: 24199712.
6. Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special? Cancer 117(5):882-3, 2011. PMID: 20960505.
7. Kamat AM, Svatek R. Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer. J Urol 182(6):2630; discussion 2631, 12/2009. e-Pub 10/2009. PMID: 19836780.
8. Kamat AM. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 182(5):2203, 11/2009. e-Pub 9/2009. PMID: 19758663.
9. Kamat AM. Intravesical BCG for bladder cancer: how much is enough? Cancer 113(4):674-6, 8/2008. PMID: 18543323.
10. Kamat AM, Fisher MB. Lymph node density: surrogate marker for quality of resection in bladder cancer? Expert Rev Anticancer Ther 7(6):777-9, Jan-Feb, 2007. PMID: 17555386.
11. Kamat AM. Outcome of penile cancer in circumcised men. J Urol 175(2):561, 2006.
12. Kamat AM, Dinney CP. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Nat Clin Pract Urol 3(9):472-473, 2006.
13. Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care? Am J Clin Onc Rev 2(11):624-637, 2003.


1. Kamat A, Chang S, Lee C, Amiel G, Beard T, Fergany A, Kames J, Menon V, Sexton W, Slaton J, Svatek R, Wilson S, Techner L, Bihrle R, Koch M, Steinberg G. Alvimopan, a peripherally acting mu-opioid receptor antagonist, accelerates gastrointestinal recovery and decreases length of hospital stay after radical cystectomy, 5/2013.
2. Kamat A. BCG Intravesical therpay: improving clinical outcomes and defining BCG failure, 5/2013.
3. Chiong, E, Hegarty, P, Davis, JW, Kamat, AM, Pisters, LL, Matin, SF. Port-Site Hernias Occurring After The Use Of Bladeless Radially Expanding. American Urological Association Annual Meeting (#893), 2010.
4. Messetti F, Anderson R, Martinez S, Nogueras Gonzalez G, Katz R, Khanna A, Grossman HB, Dinney C, Kamat A,. Prospective Clinical Trial To Evaluate Markers Of Response To Intravesical Therapy For Bladder Cancer:. American Urological Association Annual Meeting (#1471), 2010.
5. Karam JA, Shah JB, Kader AK, Svatek RS, Guo C, Grossman HB, Munsell M, Katz R, Dinney CP, Kamat AM. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. 2010 Genitourinary Cancers Symposium (#275), 2010.
6. Karam J, Shah J, Kader K, Svatek R, Guo C, Grossman HB, Munsell M, Katz R, Dinney C, Kamat A,. Prospective Trial To Identify Optimal Bladder Cancer Surveillance Protocol: Reducing Costs While Maximizing Sensitivity. American Urological Association Annual Meeting (#1177), 2010. PMID: 21426474.
7. Williams M, Pircher T, Zomorrodi M, Mikolajczyk S, Kamat A,. Recovery Of Circulating Tumor Cells In Urothelial Carcinoma Cell Lines Utilizing A Novel Antibody Based Microfluidic Cell Capture Technique. American Urological Association Annual Meeting (#975), 2010.
8. Fernandez, M, Parikh S, Dinney, CP, Grossman HB, Katz R, Matin S, Kamat, AM. The Role Of Fish In Upper Urinary Tract Surveillance After Radical Cystectomy For Bladder Cancer. American Urological Association Annual Meeting (#427), 2010. PMID: 21396845.
9. AO Siefker-Radtke, AM Kamat, DL William, NM Tannir, S Tu, LC Pagliaro, CP Dinney, RE Millikan. A Phase II rendomized four-regimen selection trial incorporating response for sequetial chemotherapy inmetastatic, unresectable urothelial cancer: Final results from the M.D. Anderson Cancer Center. Journal of Clinical Oncology 27(15S):251s (#5071), 2009.
10. Black PC, Wright JL, Brown GA, Gomez JA, Porter MP, Kamat AM, Dinney CPN, Lin DW. Differences in Survival Between patients with Sarcomatoid Carcinoma, Carcinosarcoma and Transitional Cell Carcinoma of the Bladder. American Urological Association Annual Meeting (#1647), 2007.
11. Spiess PE, Brown GA, Tannir NM, Tu SM, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Predicting Disease Progression in Patients with Viable Tumor at Post Chemotherapy RPLND. American Urological Association Annual Meeting (#834), 2007.
12. Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM, Tu SM, Evans JG, Pister LL,. Recurrence in Patients with pNO at RPLND: Can we Predict which Patients are at Risk?. American Urological Association Annual Meeting (#998), 2007.
13. Agarwal PK, Kassouf W, Dinney CPN, Munsell MF, Spiess PE, Brown GA, Grossman HB, Herr HW, Kamat AM. TNM Nodal Status Versus Lymph Node Density for Prediction of Disease-Specific Survival After Radical Cystectomy for Bladder Cancer. American Urological Association Annual Meeting (#1663), 2007.
14. Kassouf W. Agarwal PK, Herr HW, Munsell Mf, Spiess PE, Brown GA, Pisters LL, Grossman HB, Dinney CP, Kamat AM. TNM Nodal status versus lymph node density for prediction of disease-specific survival after radical cystectomy for bladder cancer. J Urol 177(4):551, 2007.
15. Black PC, Kassouf W, Brown GA, Kamat AM, Nogueras GM, Munsell M, Siefker-Radtke AO, Millikan RE, Grossman HB, Dinney CPN. Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. American Urological Association Annual Meeting (#1521), 2007.
16. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney, CPN, Kamat AM. A comparison of performance of TNM staging versus lymph node density in risk stratification of patients undergoing cystectomy for urothelial carcinoma. J Urol 175(4):1251, 2006.
17. Spiess P, Evans J, Kamat AM, Wood C, Pettaway C, Dinney C, Pisters L. Chylous Ascites after Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. J Urol 173(4):197, 2006.
18. Brown GA, Spiess PE, Bassett RL, Grossman HB, Dinney CPN, Kamat AM. Contemporary management of primary carcinomas of the female urethra. J Urol 175(4):462, 2006.
19. Spiess PE, Kassouf W, Brown GA, Kamat AM, Gomez JA, Evans J, Pisters, LL. M. D. Anderson experience in the clinical management of growing teratoma syndrome. J Urol 175(4):448, 2006.
20. Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CPN, Kamat AM. Management of primary carcinomas of the male urethra. J Urol 175(4):463, 2006.
21. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney CPN, Kamat AM. Natural history of bladder cancer in patients with P0 disease at radical cystectomy. J Urol 175(4):1233, 2006.
22. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CPN, Millikan RE. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol 175(4):1240, 2006.
23. Kassouf W, Safe S, Abdelrahim M, Chintharlapalli S, Nelkin G, Kamat AM. Activity of novel agonists of peroxisome proliferator-activated receptor gamma (PPAR-gamma) against human transitional cell tumors. J Urol 173(4):211, 2005.
24. Highshaw R, Nelkin G, Matin S, Kamat AM. Atorvastatin: Potential For Use as an Anti-Tumor Agent in Bladder Cancer. J Urol 173(4):161, 2005.
25. Kamat AM, Rosser C, Wen S, Cheung R, Lee A, Putman S, Pisters L. Body Mass Index Does Not Affect Outcome For Men Undergoing External-Beam Radiotherapy For Localized Prostate Cancer. j Urol 173(4):280, 2005.
26. Highshaw R, Dinney C, Bermejo C, Nelkin G, Kamat AM. Isolation and Characterization of metastatic variants obtained by orthotopic recycling of the papillary human transitional cell carcinoma (rt4) cell line. J Urol 173(4):159, 2005.
27. Kamat AM, Gee J, Grossman H, Dinney C, Siefer-Radtke A, Millikan R, Swanson D, Robinson T, Pisters L. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. J Urol 173(4):302, 2005.
28. Kassouf W, Leibovici D, Zhou X, Dinney C, Grossman H, Siefker-Radtke A, Pisters L, Swanson D, Kamat AM. Significance of lymph node positive disease in patients treated with neoadjuvant chemotherapy: Is adjuvant chemotherapy beneficial?. J Urol 173(4):358, 2005.
29. Kamat AM, Gee J, Dinney C, Grossman H, Swanson D, Millikan R, Robinson T, Pisters L.. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. J Urol 173(4):247, 2005. PMID: 16469571.
30. Leibovici D, Kassouf W, Kamat AM, Pisters L, Pettaway C, Dinney C. Transurethral tumor resection versus partial cystecomy for bladder preservation for muscle invasive cancer. J Urol 173(4):303, 2005.
31. Jacobsohn K, Kamat AM, Troncoso P, Shen Y, Wen S, Babaian R. Validation of selection criteria used in predicting extraprostatic cancer extension in patients undergoing nerve-sparing radical prostatectomy. J Urol 173(4):186, 2005.
32. Kassouf W, Leibovici D, Dinney C, Grossman H, Kamat AM. Validation of the concept of lymph node density in a contemporary series of patients. J Urol 173(4):358, 2005.
33. Canfield SE, Kamat AM,Sanchez-Ortiz RF, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): predictive factors for survival. J Urol 171(4):1787, 2004.
34. Khanna A, Fernandez R, Payne L, Zhang H, Bekele B, Kamat A, Caraway N, Katz RL. Telomere length is more highly associated with urothelial cancer in urinary tract cytology specimens than DNA ploidy and bladder recurrence FISH test. American Society of Cytopathology Annual Scientific Meeting, 2004.
35. Kamat AM, Riggs D, Lamm DL. Anti-tumor activity of common antibiotics against superficial bladder cancer. J Urol 169(4):988, 2003. PMID: 15028437.
36. Kamat AM, Kedar D, Bermejo C, Davis D, Radinsky R, Elliott W, Bar-Eli M, McConkey D, Dinney C. CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. J Urol 169(4):504, 2003.
37. Bermejo C, Dinney C, Kamat A, Kedar D, Mirabilis R, McConkey D, Elliott W, Bar-Eli M. Downstream signaling pathways and antiangiogenic effects of the pan-erbb tyrosine kinase inhibitor CI-1033 in a human bladder cancer cell line. J Urol 169(4):730, 2003.
38. Kamat AM, Rosser CJ, Levy LB, Chichakli R, Pisters LL. Fluctuation of > 1.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure. J Urol 169(4):1719, 2003.
39. Bermejo C, Sanchez-Ortiz R, Kamat AM, Daliani D, Pettaway C. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile carcinoma. J Urol 169(4):683, 2003.
40. Kamat AM, Karashima T, Davis DW, Dinney CPN, McConkey DJ. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. J Urol 169(4):495, 2003.
41. Kamat AM, Riggs DR, Lamm DL. Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model (MBT2). J Urol 163(4):118, 2000.
42. DeHaven JI, Anderson MI, Kamat AM, Riggs DR, Hogan TF, Lamm DL. Combined and sequential paclitaxel-based chemosensitivity in renal cell adenocarcinoma cell lines. ASCO Program Proceedings (#1296), 1999.
43. Kamat AM, DeHaven JI, Lamm DL. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. J Urol 161(4):115, 1999.
44. Kamat AM, DeHaven JI, Riggs DR, Pathak VK, Hu WS, Lamm DL. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. J Urol 64(4):119, 1999.

Book Chapters

1. Abel EJ, Kamat AM. Bladder Cancer. In: Atlas of Bladder Cancer. Ed(s) David Staskin. Springer: New York, 221, 2010. ISBN: 978-1-57340-307-8.
2. Kamat AM, Nseyo UO. Dysuria. In: Five Minute Urology Consult. Ed(s) Gomella LG. Lippincott: Philadelphia, 28-29, 2000.
3. Kamat AM. Laboratory investigation in urology. In: Urology for Primary Care Physicians. Ed(s) Nseyo UO, Weinman E, Lamm DL. WB Saunders, 23-31, 1999.

Letters to the Editor

1. Amrhein J, Kamat AM, Morales A. Re: Jarow JP et al. Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). Urology 84(2):494-5, 8/2014. PMID: 25065995.

Manuals, Teaching Aids, Other Teaching Publications

1. Kamat AM. When to Use Intravesical Therapy for Bladder Cancer. Renal & Urology News, 2007.
2. Kamat AM. Bladder Cancer Options - State of the Art Patient Care. 1 & 2, 2005.
3. Kamat AM. Prostate Cancer Guidlines. HealthGate: Burlington, MA, 2005.
4. Kamat AM. BCG Immunotherapy: Bladder Cancer and Beyond. CME Supplement to "Renal & Urology News", 2004.


1. Newsletter. "Ask the Doctor", BCAN Newsletter, April 2007.

Last updated: 5/18/2016